Quest Diagnostics Incorporated ($DGX) Stock Forecast: Up 7.7% Today

What is Quest Diagnostics Incorporated?

Quest Diagnostics (DGX) is a leading provider of diagnostic testing, information, and services. The company offers a wide range of services to patients, healthcare providers, and pharmaceutical companies.

Why is Quest Diagnostics Incorporated going up?

DGX stock is up 7.7% on Apr 22, 2025 19:47

• Quest Diagnostics (DGX) stock showed a strong bullish movement.
• The company surpassed expectations with its first quarter 2025 earnings and revenues, outperforming analyst projections.
• The stock's upward trend can be attributed to the favorable earnings report and sustained growth over the past 5 years.
• Investor optimism in Quest Diagnostics' performance and market position is likely driving the stock price increase.

DGX Price Chart

DGX Technical Analysis

DGX News

Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up

DGX delivers solid top-line growth in the first quarter of 2025.

https://www.zacks.com/stock/news/2452856/quest-diagnostics-q1-earnings-revenues-top-estimates-stock-up

Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday - Akso Health ( NASDAQ:AHG ) , Bitdeer Technologies ( NASDAQ:BTDR )

U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday. Shares of Quest Diagnostics Incorporated DGX rose sharply during Tuesday's session following better-than-expected first-quarter earnings.

https://www.benzinga.com/25/04/44924973/quest-diagnostics-posts-better-than-expected-earnings-joins-pentair-3m-danaher-and-other-big-stocks-moving-higher

Quest Diagnostics ( DGX ) Q1 Earnings and Revenues Beat Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 2.79% and 1.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2452443/quest-diagnostics-dgx-q1-earnings-and-revenues-beat-estimates

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Quest Diagnostics ( NYSE:DGX )

Quest Diagnostics DGX has outperformed the market over the past 5 years by 291.15% on an annualized basis producing an average annual return of 305.18%. Currently, Quest Diagnostics has a market capitalization of $18.18 billion.

https://www.benzinga.com/insights/news/25/04/44887910/1000-invested-in-this-stock-5-years-ago-would-be-worth-this-much-today

Trending Today

NEAR Protocol ($NEAR) Crypto Forecast: Down 5.7% Today

Movement ($MOVE) Crypto Forecast: Down 6.7% Today

Worldcoin ($WLD) Crypto Forecast: Down 5.2% Today

Sui ($SUI) Crypto Forecast: Down 5.1% Today

Memecoin ($MEME) Crypto Forecast: Down 5.5% Today

Bitcoin Cash ($BCH) Crypto Forecast: Up 5.0% Today

Immutable ($IMX) Crypto Forecast: Up 10.4% Today

Ethena ($ENA) Crypto Forecast: Down 5.2% Today

Natural Gas ($GAS) Commodity Forecast: Up 5.9% Today

Sirius XM Holdings Inc. ($SIRI) Stock Forecast: Up 5.1% Today

Quest Diagnostics Incorporated Price History

30.00.2025 - DGX Stock was up 6.5%

• The company reported strong fourth-quarter earnings and revenue that exceeded analyst expectations, showcasing robust performance in their core business.
• Despite the positive financial results, the stock initially experienced a dip, potentially influenced by profit-taking or short-term market fluctuations.
• Quest Diagnostics' improved margins demonstrate effective cost management and enhanced operational efficiency, which may have contributed to the positive movement in the stock.
• Investors reacted favorably to the company's overall solid financial performance, leading to the bullish market activity observed.

30.00.2025 - DGX Stock was up 5.1%

• Q4 earnings and revenues for Quest Diagnostics (DGX) exceeded estimates, reflecting strong financial performance.
• The positive earnings surprise is likely to have bolstered investor confidence in the company's growth prospects.
• Strong quarterly results may have drawn new investors and increased buying interest in DGX shares.
• The better-than-expected performance could indicate a positive outlook for Quest Diagnostics, potentially leading to further price appreciation in the stock.

22.09.2024 - DGX Stock was up 6.2%

• Quest Diagnostics (DGX) displayed a strong bullish movement after surpassing third-quarter financial expectations and providing positive revenue guidance for FY24.
• The company's exceptional performance in Q3, exceeding consensus on adjusted earnings per share and showing significant year-over-year sales growth, led to a favorable market response towards DGX.
• Optimistic future earnings growth prospects from the CEO and successful acquisition of new customers bolstered investor confidence in Quest Diagnostics.
• The favorable reaction to Quest Diagnostics' outperformance in earnings and revenue outlook bodes well for its stock, in contrast to the modest decline in Myriad Genetics shares following a partnership announcement.

22.09.2024 - DGX Stock was up 5.2%

• Quest Diagnostics (DGX) exceeded Q3 earnings and revenue estimates, indicating strong financial performance and investor confidence in the company's growth prospects.
• The positive earnings surprise may have fueled investor optimism and attracted more buyers to the stock, driving the bullish movement.
• The company's ability to outperform expectations suggests efficient management and a competitive position in the healthcare industry, contributing to the upward momentum in the stock price.
• Overall, the market responded positively to Quest Diagnostics' robust financial results, setting a bullish tone for the stock in the near term.

19.02.2025 - DGX Stock was down 5.1%

• Quest Diagnostics (DGX) experienced a bearish movement today.
• Aveanna (AVAH) surging 6.2% might have diverted investor attention away from DGX.
• The lack of positive earnings estimate revisions for Aveanna could have prompted investors to move funds out of DGX and into more promising opportunities.
• The shift in focus towards Aveanna's potential gains may have contributed to the bearish movement in Quest Diagnostics (DGX) today.

29.03.2024 - DGX Stock was up 4.1%

• Quest Diagnostics (DGX) received a "buy" rating and an increased stock target, reflecting positive sentiment from analysts and investors.
• During Q1, the company experienced a notable surge in sales, surpassing estimates for adjusted EPS and achieving growth in total revenues for the first time in almost three years. This positive financial performance likely contributed to the stock's upward trend.
• Despite beating earnings expectations, Quest Diagnostics (DGX) observed a decrease in margins in Q1, which could raise concerns among investors. Nevertheless, the overall revenue growth and strong performance overshadowed this issue, pushing the stock towards a bullish market movement.

23.03.2024 - DGX Stock was up 7.7%

• Quest Diagnostics (DGX) exceeded Q1 earnings and revenue estimates, demonstrating strong financial performance.
• The company's first-quarter financial results showed increased revenues and raised guidance for the full year 2024, suggesting positive growth prospects.
• The market responded favorably to Quest Diagnostics surpassing expectations and revising its guidance upwards, leading to an increase in the stock price.
• Investor confidence in the company's future performance is evident from the bullish trend in the stock.

23.06.2024 - DGX Stock was down 5.5%

• Despite surpassing revenue expectations, DGX recorded a downturn in profits during the second quarter.
• The failure to meet GAAP EPS predictions could be a factor in the stock's decline.
• Investors' reactions may have been unfavorable due to a slight drop in reported diluted earnings per share for the quarter.
• The market's response might also be linked to the company's adjusted diluted EPS performance and its revised full-year revenue outlook.

23.06.2024 - DGX Stock was down 5.1%

• Despite surpassing revenue expectations and raising its 2024 outlook, Quest Diagnostics (DGX) saw a decline in its stock price.
• The company's slight miss in GAAP EPS estimates may have influenced the negative market response, despite its strong base business growth.
• Investors might have anticipated higher earnings per share, prompting profit-taking and a temporary stock price drop.
• Concerns among market participants have arisen over the Q2 profit decrease, even though it outperformed estimates, indicating a potential necessity for cost management or operational enhancements for future growth.

22.03.2025 - DGX Stock was up 7.7%

• Quest Diagnostics (DGX) stock showed a strong bullish movement.
• The company surpassed expectations with its first quarter 2025 earnings and revenues, outperforming analyst projections.
• The stock's upward trend can be attributed to the favorable earnings report and sustained growth over the past 5 years.
• Investor optimism in Quest Diagnostics' performance and market position is likely driving the stock price increase.

22.03.2025 - DGX Stock was up 5.8%

• Strong Q1 earnings and revenues exceeded expectations, signaling robust financial performance and potentially favorable future outlook.
• Over the last 5 years, the stock has consistently outperformed the market, demonstrating steady growth and investor trust.
• Although there was a minor decline in stock price in the past month, the significant rise over the last year indicates sustained positive momentum.
• Anticipated earnings growth is reinforcing the bullish trend, implying ongoing profitability and investor confidence in the company's prospects.

22.03.2025 - DGX Stock was up 8.2%

• Quest Diagnostics (DGX) experienced a robust upward movement today.
• The company exceeded earnings expectations for the first quarter, resulting in a notable surge in its stock price.
• Over the past 5 years, Quest Diagnostics has consistently outperformed, showcasing an impressive average annual return that has likely boosted investor confidence and interest in the stock.
• Strong earnings and revenue results for the quarter ending in March 2025 indicate a solid performance by the company, potentially fueling additional investor confidence and driving the stock price upwards.